GlaxoSmithKline plc (ADR) (NYSE:GSK) is losing some of its long-standing executives at a time when the company is scrambling for a return to profitability. The British pharma giant said Tuesday that its vaccines chairman, Moncef Slaoui, will retire on June 30, 2017 after spending nearly three decades with the company. He will relinquish his board seat, which he has held since 2006 — on March 31, 2017. Andrew Witty, CEO GSK since 2008, is scheduled to retire around the same time.
